* Madrigal pharmaceuticals inc - private placement offering of approximately 1.97 million shares of its series a convertible preferred stock

* Madrigal pharmaceuticals inc says expects to use proceeds from offering primarily to support ongoing clinical development of its lead compound, mgl-3196 Source text for Eikon: Further company coverage: